2001
Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo
Hartlapp I, Abe R, Saeed R, Peng T, Voelter W, Bucala R, Metz C. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. The FASEB Journal 2001, 15: 2215-2224. PMID: 11641248, DOI: 10.1096/fj.01-0049com.Peer-Reviewed Original ResearchConceptsBlood vessel formationAngiogenic phenotypeVessel formationMesenchymal cell typesEndothelial cell invasionEndothelial cellsExtracellular matrix-degrading enzymesEndothelial cell migrationGrowth factorCellular microenvironmentMatrix-degrading enzymesCell invasionCell migrationCell typesCultured endothelial cellsTube formationHematopoietic growth factorsPromotion of angiogenesisPhenotypeAngiogenesis modelMicrovascular endothelial cellsCultured fibrocytesEnzymeAngiogenesisVivo
2000
De Novo Expression of Macrophage Migration Inhibitory Factor in Atherogenesis in Rabbits
Lin S, Yu X, Chen Y, Huang X, Metz C, Bucala R, Lau C, Lan H. De Novo Expression of Macrophage Migration Inhibitory Factor in Atherogenesis in Rabbits. Circulation Research 2000, 87: 1202-1208. PMID: 11110779, DOI: 10.1161/01.res.87.12.1202.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorUpregulation of MIFSmooth muscle cellsVascular endothelial cellsMIF expressionMigration inhibitory factorFatty streak lesion formationInhibitory factorAbility of MIFIntercellular adhesion molecule-1 expressionAdhesion molecule-1 expressionFoam cell-rich lesionsNew Zealand white rabbitsAccumulation of macrophagesMolecule-1 expressionTranscriptase-polymerase chain reactionHypercholesterolemic rabbit modelEarly fatty streaksZealand white rabbitsDe novo expressionMacrophage-mediated diseasesMIF levelsCholesterol dietMIF mRNANormal diet
1999
An Essential Role for Macrophage Migration Inhibitory Factor (MIF) in Angiogenesis and the Growth of a Murine Lymphoma
Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R. An Essential Role for Macrophage Migration Inhibitory Factor (MIF) in Angiogenesis and the Growth of a Murine Lymphoma. Molecular Medicine 1999, 5: 181-191. PMID: 10404515, PMCID: PMC2230298, DOI: 10.1007/bf03402061.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodiesCell DivisionCollagenDisease Models, AnimalDrug CombinationsEndothelium, VascularHumansImmunohistochemistryLamininLymphoma, B-CellMacrophage Migration-Inhibitory FactorsMiceMice, Inbred StrainsNeovascularization, PathologicOligonucleotides, AntisenseProteoglycansTumor Cells, CulturedConceptsMacrophage migration inhibitory factorRole of MIFAnti-MIF monoclonal antibodyMigration inhibitory factorB-cell lymphomaMonoclonal antibodiesCell lymphomaEffect of MIFBackgroundMacrophage migration inhibitory factorInhibitory factorC3H/HeN miceTumor-associated neovasculatureActivation of macrophagesAutocrine growth factorMicrovascular endothelial cellsCultured microvascular endothelial cellsAnti-neoplastic agentsNew blood vessel formationSolid tumor biologyEndothelial cell proliferationMIF expressionHeN miceSyngeneic modelMIF proteinTumor response
1997
Elevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs
Stitt A, He C, Friedman S, Scher L, Rossi P, Ong L, Founds H, Li Y, Bucala R, Vlassara H. Elevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs. Molecular Medicine 1997, 3: 617-627. PMID: 9323713, PMCID: PMC2230092, DOI: 10.1007/bf03401819.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAgingApolipoproteins BArteriosclerosisCarotid ArteriesCollagenEndothelium, VascularEnzyme-Linked Immunosorbent AssayFemaleGlycation End Products, AdvancedHumansImmunohistochemistryMacrophagesMaleMicroscopy, FluorescenceMiddle AgedReceptor for Advanced Glycation End ProductsReceptors, ImmunologicRegression AnalysisConceptsSmooth muscle cellsAGE-specific receptorsMononuclear cellsAtherosclerotic vascular diseaseOcclusive atherosclerotic diseaseDevelopment of hyperlipidemiaLipid-laden macrophagesYoung healthy personsEarly-stage lesionsCardiac bypass patientsAGE-R1Nondiabetic patientsAsymptomatic patientsAsymptomatic personsBypass patientsNormolipidemic patientsAtherosclerotic diseaseDistribution of ageVascular diseaseInflammatory responseLate-stage plaquesAtheromatous lesionsEarly lesionsFatty streaksNondiabetic etiology
1995
Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition
Bucala R, Vlassara H. Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition. Blood Purification 1995, 13: 160-170. PMID: 7619388, DOI: 10.1159/000170199.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCarbohydratesDiabetic NephropathiesEndothelium, VascularGlycosylationGuanidinesHumansLipoproteinsConceptsAdvanced glycosylation endproductsDiabetic renal diseaseNormal renal functionInactivate nitric oxideSpecific therapeutic modalitiesTissue LDL receptorsForms of LDLRenal functionRenal diseaseLDL levelsTherapeutic modalitiesVascular permeabilityPathophysiological significanceAdvanced glycosylationLipoprotein depositionPharmacological inhibitionLDL receptorClinical measurementsNitric oxideEndothelial cellsMarked increaseMiddle moleculesLDLToxic effectsEndproducts